Litigation Details for Allergan, Inc. v. Sandoz, Inc. (Fed. Cir. 2015)
✉ Email this page to a colleague
Allergan, Inc. v. Sandoz, Inc. (Fed. Cir. 2015)
Docket | ⤷ Sign Up | Date Filed | 2015-10-19 |
Court | Court of Appeals for the Federal Circuit | Date Terminated | |
Cause | Assigned To | ||
Jury Demand | Referred To | ||
Patents | 6,403,649; 7,351,404; 7,388,029; 8,038,988; 8,101,161; 8,263,054; 8,906,962; 8,926,953 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Allergan, Inc. v. Sandoz, Inc.
Details for Allergan, Inc. v. Sandoz, Inc. (Fed. Cir. 2015)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2016-03-25 | 38 | in Ophthalmology, 1993, 44-50, 4(11). 6,403,649 Bl 612002 Woodward …However, the ’953 patent is related to U.S. Patent No. 7,351,404, and the ’404 patent was the subject …assert newly issued patent claims that are patentably distinct from its earlier patents. Allergan’s Latisse…different asserted patent (U.S. Patent No. 7,388,029, which is unrelated to the patent-in-suit here) and…three additional patents that were continuations of the ’404 patent, namely U.S. Patent Nos. 8,038,988; | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |